US · Healthcare · Biotechnology
EPS came in at -0.35 against a street estimate of -0.22 — a miss of 59.1%.
Analysts rate Candel Therapeutics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $21.00.
| Fund | Stake |
|---|---|
| FMR Inc | 14.36% |
| RTW INVESTMENTS, LLC | 8.39% |
| Saturn V Capital Management LLC | 4.32% |
| BlackRock Inc | 4.06% |
| Portolan Capital Management, LLC | 3.78% |
| Vanguard Capital Management, LLC | 3.22% |
| Vestal Point Capital LP | 1.47% |
| Millennium Management LLC | 1.43% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 CANDEL THERAPEUTICS, INC. – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Board of Directors expanded from 10 to 11 members on September 6, 2026 • Mar | 2026-09-10 |
| Reg FD disclosure · Q3 2026 CANDEL THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Candel Therapeutics, Inc. (Ticker: CADL, Nasdaq) • Filing Date: September 9, 202 | 2026-09-09 |
| Quarterly report · Q2 2026 CANDEL THERAPEUTICS, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $201.6 million as of June 30, 2026 (up from $119.7 million at D | 2026-08-13 |
| Results announced · Q3 2026 CANDEL THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $201.6 million as of June 30, 2026, up from $119.7 million at Decemb | 2026-08-13 |
| Shareholder vote results · Q2 2026 CANDEL THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 23, 2026 • 73,270,239 outstanding shares of common stock as of A | 2026-06-24 |
| Board / officer change · Q2 2026 CANDEL THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • CFO Charles Schoch's annual base salary: $468,600 • Target annual bonus: 40% of base sala | 2026-06-16 |
| Reg FD disclosure · Q2 2026 CANDEL THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics or numerical results disclosed in this 8-K filing itself • | 2026-05-15 |
| Quarterly report · Q1 2026 CANDEL THERAPEUTICS, INC. – 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash position: $194.8 million as of March 31, 2026 (up from $119.7 million at | 2026-05-14 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Candel Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.